Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions worldwide. This complex liver disorder ranges from simple steatosis to more severe forms, including metabolic dysfunction-associated steatohepatitis (MASH), which may progress to fibrosis, cirrhosis, and even liver cancer. The latest insights into transcription factors provide a deeper understanding of the disease’s progression and potential therapeutic interventions.
Transcription factors are critical proteins that regulate gene expression, playing a pivotal role in controlling key processes such as lipid metabolism, inflammation, apoptosis, and fibrosis in MAFLD. Several transcription factors, including farnesoid X receptor (FXR), peroxisome proliferator-activated receptors…